heading@domain@Max Phase@# locations@# trials@developers
Epratuzumab–SN-38@@@0@0@Immunomedics
IMGN-242@Oncology@2@0@0@IMMUNOGEN
IMGN 289@@@0@0@IMMUNOGEN
RG-7636 | Anti-ETBR@Oncology@1@0@0@Genentech | Roche
SC16LD6.5@Oncology@3@35@7@Stemcentrx | AbbVie
AGS 16C3F | AGS-16M8F | AGS-16C3F@@1@0@0@Astellas | Agensys
iratumumab | MDX-060@@2@0@0@Bristol Myers Squibb | Medarex
KTN0182A@@Preclinical@0@0@Kolltan
RG7986@@@0@0@Genentech | Roche
EDO-772P/B776@@@0@0@Mundipharma EDO
EDO-B278@@@0@0@Mundipharma EDO
CD22-4AP@Oncology | Hematology@1@2@1@Catalent | Triphase Accelerator Corporation
KTN0125@@Preclinical@0@0@Kolltan
Anti-Ly6E DLYE5953A Lymphocyte antigen 6 complex Locus E RG-7841 | RG-7841 | Anti-Ly6E | DLYE5953A@Oncology@1@0@0@Genentech | Seagen | Roche
CDX014 | CR014-vcMMAE | CR 014-vcMMAE | CDX-014@Oncology@2@0@0@Celldex
Hertuzumab Vedotin | Hertuzumab-vcMMAE@Oncology@2@0@0@Rongchang | MabPlex
B7-H3 ADC | DS-7300@Oncology@2@24@1@DAIICHI SANKYO
ADCT-502@Oncology@1@0@0@ADC Therapeutics
SGN-CD19B@Hematology@1@0@0@Seagen
SC-006 | SC006@Oncology@@0@0@Stemcentrx | AbbVie
AMG172@Oncology@1@3@1@Amgen
BIIB015 | BIIB-015@Oncology@1@1@1@Biogen
IMGN388 | CNTO 95-DM4 | CNTO 365 | IMGN-388@Oncology@1@0@0@IMMUNOGEN
hLL1 | CD74-DOX | IMMU-110 | hLL1-DOX | Milatuzumab doxorubicin | MEDI-115@Oncology@3@54@37@Immunomedics
RG7450 | Vandortuzumab vedotin | DSTP3086S | RG-7450 | MSTP2109A | DSTP-3086S | Anti-STEAP1 ADC@Oncology@2@0@0@Genentech | Roche
DFRF 4539A | RG 7598 | RG-7598 | RG7598@Oncology@1@0@0@Genentech | Roche
Vorsetuzumab mafodotin | SGN-75@Oncology | Hematology | Immunology@2@2@2@Seagen
PF06688992 | GD3 ADC | PF-06688992@Oncology; Hematology@1@1@1@Pfizer
SGN-CD352a@Oncology, Hematology@1@0@0@Seagen
AbGn-110@Oncology@Preclinical@0@0@AbGenomics BV
AbGn-108@Oncology@@0@0@AbGenomics BV
AB-3A4 | AB-3A4-ADC | AB-3A4-vcMMAE | AB-3A4 ADC@Oncology@@0@0@Alethia
ALT-Q5@Oncology@Preclinical@0@0@Alteogen
RG 7600 | DMOT-4039A | DMOT4039A | RG7600@@1@0@0@Genentech | Roche
PF-06263507 | A1-mafodotin | PF06263507 | A1-mcMMAF | PF 06263507 | Anti-5T4 monoclonal@Oncology@2@1@1@Oxford BioMedica | Pfizer | WYETH
PF 06664178 | PF06664178 | PF-06664178 | RN927C@Oncology@@0@0@Rinat | Pfizer | WYETH
superseding SGN-75 | SGN-CD70A | SGN CD70 A@Oncology; Hematology.@1@2@2@Seagen
DSTA4637S | RG7861 | Anti-S. aureus TAC@Infectious diseases@1@0@0@Genentech
MLN-2704 | MLN2704@Oncology@2@1@2@Takeda | Millennium
BAY 79-4620 | 3ee9 | BAY 794620 | BAY79-4620@Oncology@1@0@0@Bayer
Anti-proto-oncogene protein c-kit IgG1/kappa -maitansine | LOP628 | LOP-628 | LOP 628 | Anti-c-kit humanised IgG1/κ -maitansine@Oncology@3@1@2@Novartis
SGN-CD123A@@1@0@0@
SAR428926 | SAR428926 SAR 428926@Oncology@1@0@0@IMMUNOGEN | Sanofi
CBT-161 | Anti-cMET ADC@Oncology@@0@0@Sorrento Therapeutics
Anti-NOTCH3 ADC | PF06650808 | PF-06650808 | Anti-NOTCH3-ADC | PF-6650808@Oncology@1@0@0@Pfizer | WYETH
AGS 62P1 | AGS62P1@Oncology@1@0@0@Astellas | Agensys
ADCM-E7974 | NC-6201@Oncology@Preclinical@0@0@NanoCarrier (Japan) | Eisai
NV101 | Doxorubicin-anti-CD99@Oncology@3@54@37@NanoValent
NV103 | Irinotecan-anti-CD99@Oncology@2@16@1@NanoValent
NV102 | Doxorubicin-anti-CD19@Oncology@3@54@37@NanoValent
EDC9 | EDC-CD20@Oncology@Preclinical@0@0@Centrose | Wisconsin Alumni Research Foundation - WARF
DYS-ADC | EDC-1 | DYS-EDC | EDC1@Oncology@Preclinical@0@0@Centrose | Wisconsin Alumni Research Foundation - WARF
ASN-004 ASN004 ASN 004 | ASN 004 | ASN-004@Oncology@1@1@1@Asana BioSciences
MEN 1309 MEN1309 OBT076 | MEN1309 | OBT076@Hematology; Oncology@1@5@1@Oxford BioTherapeutics | Menarini Ricerche
Anti-HER-3 | anti-HER-3 ADC@Oncology@Preclinical@0@0@MediaPharma
MK8109 | Vintafolide | VYNFINIT® | EC145/MK 8109 | MK 8109 | EC145@Oncology@@0@0@Merck Sharp & Dohme | Endocyte
EC2629@Oncology@Preclinical@0@0@Endocyte
PF-06647263 | anti-EFNA4-ADC | PF-06647263 EFNA4-ADC@Oncology@1@0@0@Pfizer
MEDI-547 | MEDI547@Oncology@1@0@0@MedImmune
EC1169@Oncology@1@0@0@Endocyte
ABV176 | ABBV-176 | ABBV176 | ABBV 176@Oncology@1@0@0@AbbVie
anti-CD70 ADC | CD70 ADC | Anti-CD70-ADC | CD70-ADC@Oncology Hematology@Preclinical@0@0@Ambrx
CD184-Dasatinib-ADC | CD184-Dasatinib@Non-Oncology; Non-Hematology;@Preclinical@0@0@Ambrx
CD163-dexamethasone ADC | anti-CD163-dexamethasone | anti-CD163-dexamethasone ADC | Cymac-001@Non-Oncology; Non-Hematology; Inflammation;@3@35@11@Affinicon
CD70-glucocorticoid ADC@Non-Oncology; Non-Hematology; Inflammation@Preclinical@0@0@Ambrx
CD184-FK506@Non-Oncology; Non-hematology; Inflammation@Preclinical@0@0@Ambrx
HKT288 | Maytansine-based ADC HKT-288 | HKT-288 | CDH6-ADC@Oncology@1@0@0@Novartis
PCA062 PCA-062 | PCA062 | PCA-062@Oncology@1@0@0@IMMUNOGEN | Novartis
ZV203@Oncology@Preclinical@0@0@Concortis
c-MET ADC@Oncology@Preclinical@0@0@Concortis
EP-400@Oncology Hematology@@0@0@Esperance
IMAB362-vcMMAE@Oncology@Preclinical@0@0@Astellas | Ganymed
Anti-endosialin-MC-VC-PABC-MMAE@Oncology@Preclinical@0@0@Genzyme
HTI-1511@Oncology@Preclinical@0@0@Halozyme
IMB-202@Oncology@Preclinical@0@0@ImmunoBiochem
IMB-201@Oncology@Preclinical@0@0@ImmunoBiochem
IGN523@Oncology@@0@0@Igenica
IGN786@Oncology Hematology@Preclinical@0@0@Igenica
LCB14-15nm@Oncology@@0@0@Takeda | Legochem
LCB14-17nn@Oncology@@0@0@Legochem
anti-CD37 ADC | LCB14-15xx | NNV019@Oncology | Oncology Hematology@@0@0@Y-Biologics | Nordic Nanovector | Legochem
AR-001 | YBK-001 | YBL-001@Oncology@@0@0@Y-Biologics
LCB14-19nm@Oncology@@0@0@Samsung Medical Center | Legochem
LCB14-2nm@Oncology@@0@0@Seasun Biomaterials | Legochem
Trastuzumab-LC-LBG-MMAF Herceptin-LC-LBG-MMAF | LCB14 0110 | Herceptin-LC-LBG-MMAF | LCB14-0110@Oncology@3@72@20@Legochem | Shanghai Fosun
Anti-ADAM9-sulfoSPDB-DM4 | Anti-ADAM9 ADC@Oncology@Preclinical@0@0@IMMUNOGEN | MacroGenics
anti-TEM-1 | TEM-1-ADC | Anti-TEM-1@Oncology@@0@0@MediaPharma
anti-CD22 Anthracycline-Based | Anti-CD22-NMS249 | anti-CD22-NMS249 | Anti-CD22 Anthracycline-Based ADC@Oncology; Hematology;@Preclinical@0@0@Genentech
Azonafide-ADC@Oncology@Preclinical@0@0@Oncolinx
Anti-MTX3:Nigrin | OMTX503@Oncology@Preclinical@0@0@Oncomatryx
OMTX705 | Anti-MTX5:Cytolysin ADC@Oncology@1@2@1@Oncomatryx
SNG-8023 ADC@Oncology@Preclinical@0@0@Shenogen Pharma
Anti-TM4SF1 ADC@Oncology@Preclinical@0@0@Pfizer | Angiex
TGM-004@Oncology@@0@0@Targetome SA
TGM-005@Oncology@@0@0@Targetome SA
TGM-001@Oncology@@0@0@Targetome SA
TGM-002@Oncology@@0@0@Targetome SA
TGM-003@Oncology@@0@0@Targetome SA
Anti-Prolactin Receptor | Anti-PRLR-ADC | PRLR | REGN2878-DM1@Oncology@@0@0@Regeneron
HuMAB-5B1-ATAC@Oncology@Preclinical@0@0@MabVax | Heidelberg Pharma | Wilex
anti-CD19 ADC | Anti-CD19 ADC | Anti-CD19 ATAC@Oncology; Hematology@Preclinical@0@0@Wilex | Heidelberg Pharma
LY3076226 | ADC LY3076226 | Anti-fibroblast Growth Factor Receptor 3 | Anti-FGFR3 ADC LY3076226@Oncology@1@2@1@Eli Lilly
IMMU-140 | anti-HLA-DR-SN-38 ADC@Oncology / Hematology@@0@0@Immunomedics
MI130004@@Preclinical@0@0@PharmaMar
@Oncology | Hematology@Preclinical@0@0@Siamab
AVID300 | AVID 300@Oncology | Hemtology@Preclinical@0@0@Formation Biologics (Forbius)
IMAB027-vcMMAE@Oncology | Hematology@Preclinical@0@0@Astellas | Ganymed
Satoreotide tetraxetan@@@0@0@
Tacatuzumab Tetraxetan@@@0@0@
ADCT-701@Oncology@Preclinical@0@0@ADC Therapeutics
EV20/MMAF@Oncology@Preclinical@0@0@MediaPharma
IMGN779 | IMGN 779@Oncology@1@0@0@IMMUNOGEN
anti-GPC2 ADC | D3-GPC2-PBD@Oncology@Preclinical@0@0@
VIS705@Antibacterials@Preclinical@0@0@Visterra
IMGN-633 | AVE9633@Oncology@@0@0@IMMUNOGEN
Anti-CD44v6 | Anti-CD44v6-DM1 | Bivatuzumab mertansine | BIWI-1 | CD44v6-DM1@Oncology@1@0@2@IMMUNOGEN | Boehringer Ingelheim
UC-961ADC3 | Cirmtuzumab Vedotin | Cirmtuzumab Vedotin UC-961ADC3@Oncology@@0@0@
GM103@Oncology@@0@0@GamaMabs
¹³¹I-chTNT-1/B mAb | Derlotuximab Biotin@Oncology@@0@0@Peregrine Pharmaceuticals
DT2219ARL | IND100780 | GTB-1550 | OXS-1550 | DT-2219ARL | GTB-1550 OXS-1550 | DT2219  Also known as: Anti-CD19-anti-CD22-diphtheria-toxin-fusion-protein@Oncology@2@1@1@Georgetown Translational (Oxis Biotech)
IKS01@Oncology@1@1@1@Iksuda
IKS02@Oncology@@0@0@Iksuda
IKS03@Oncology@@0@0@Iksuda
IKS04@Oncology@@0@0@Iksuda
NBE-002 – ROR-1 | NBE-002 NBE-002 - ROR-1@Oncology@2@0@0@NBE Therapeutics
NBE-003@Oncology@@0@0@NBE Therapeutics
NBE-001@Oncology@@0@0@NBE Therapeutics
SGN-19A SGN-CD19A hBU12-491 | Denintuzumab mafodotin | hBU12-491 | SGN-19A | SGN-CD19A@Oncology / Hematology@2@2@3@Seagen
Depatuxizumab Mafodotin | ABT-414 | ABT-414 ABT-414/806 Depatux-M@Oncology@3@32@5@AbbVie
DNIB0600A | Lifastuzumab Vedotin | MNIB2126A  Anti-NaPi2b ADC RG-7599 | RG-7599@Oncology@2@0@0@Genentech | Roche
Anti-MUC16 ADC | DMUC5754A | Sofituzumab vedotin | RG7458@Oncology@2@1@1@Roche
CDP-671 | CMB-401 | hCTMO1-calicheamicin | hCTMO1-calicheamicin CDP-671@Oncology@2@0@0@Pfizer | Celltech | WYETH
BR96-DOX | SGN-15 | SGN15 SGN 15 SGN-15 BMS-182248 BR96-DOX cBR96-doxorubicin | BMS-182248@Oncology@3@54@42@Bristol Myers Squibb | Seagen
BAY 1187982 | BAY 1187982 BAY1187982 FGFR2-ADC | Aprutumab ixadotin@Oncology@1@0@0@Bayer
EC-mAb | h2H12ec-SGD-1910 | SGN-CD33A | Vadastuximab talirine | h2H12ec-mc-val-ala-SGD-1882@Oncology, Hematoloy, Immunology@3@1@2@Seagen
Cantuzumab mertansine | huC242-DM1 | SB408075 | SB-408075@Oncology@2@0@0@IMMUNOGEN | GlaxoSmithKline
Anetumab Ravtansine | BAY 94-9343@Oncology@2@18@9@Bayer
SAR 3419 | SAR3419 | Coltuximab Ravtansine@Oncology / Hematology@2@12@2@IMMUNOGEN | Sanofi
Azintuxizumab Vedotin | ABBV-838 | ABBV-838 ABBV838@Oncology / Hematology@2@0@0@AbbVie
Clivatuzumab Tetraxetan | hPAM4 | hPAM4-DOTA | hPAM4 IgG-DOTA@Oncology@3@0@0@Immunomedics
Epitumomab cituxetan | Anti-MUC1 Therapeutic@Oncology@3@0@0@
Ibritumomab tiuxetan | In-111 Zevalin Y-90 Zevalin@Oncology@4@0@0@Biogen | Schering
BESPONSA® | CMC-544 CMC544 | Inotuzumab ozogamicin | CMC-544@Oncology/Hematology@Approved@36@19@Pfizer | WYETH
Laprituximab emtansine | IMGN-289 IMGN289 J2898A-SMCC-DM1 | IMGN-289 | IMGN289@Oncology@3@40@34@IMMUNOGEN
BAY 1129980 | BAY 1129980 BAY-1129980 BAY1129980  Other synonyms  Anti-C4.4a - s - Bayer Anti-LY6-PLAUR domain containing 3 - s - Bayer Anti-LYPD3 - s - Bayer | LYPD3 protein-directed - s - Bayer | Lupartumab amadotin@Oncology@1@0@0@Bayer
177lu | Lilotomab satetraxetan | lutetium | lilotomab satetraxetan 177lu lilotomab satetraxetan 177lu-DOTA-HH1@Oncology | Oncology Hematology@Approved@1@1@Novartis | Nordic Nanovector | Endocyte
Debio 1562 | IMGN529 | K7153A-SMCC-DM1 | Naratuximab emtansine | naratuximab emtansine | K7153A@Oncology | Hematology@2@0@0@Debiopharm | IMMUNOGEN
RO5541072-000 | DCDT2980S | FCU2803 | RG-7593 | ACD22-VCMMAE | DCDT-2989S | Pinatuzumab vedotin@Oncology | Hematology@2@6@2@Genentech | Roche
Polivy™ | ACD79B-VCMMAE | Polatuzumab vedotin | RG-7596 | DCDS4501A | FCU2711 | DCDS-4501A | RO5541077-000@Oncology | Hematology@Approved@40@34@Genentech | Roche
BL-B029A1 | BL-B029A1 BL B029A1@Oncology@Preclinical@0@0@Systimmune
BL-M005A2 | BL M005A2 BL-M005A2@Oncology@Preclinical@0@0@Systimmune
BL-M002A2 | BL M002A2 BL-M002A2@Oncology@Preclinical@0@0@Systimmune
AVID100 | AVID 100 anti-EGFR ADC@Oncology@2@1@1@Formation Biologics (Forbius)
HM2-MMAE | ALT-P7 ALT-P7 | ALT-P7@Oncology@1@1@1@Alteogen | 3SBIO
T-DM1 | Ado-Trastuzumab Emtansine T-DM1 Trastuzumab-DM1 Trastuzumab-MCC-DM1 PRO132365 PRO 132365 RG3502 | Kadcyla® | Trastuzumab Emtansine@Oncology@Approved@72@66@Genentech | Roche
TAK-522 | XMT-1522 | XMT1522 TAK-522@Oncology@1@1@1@Takeda | Mersana
ARX788 HER2 ADC | ARX788@Oncology@2@5@4@Ambrx
Nano-doxorubicin | MM-302@@3@54@37@Merrimack
Bstrongximab-ADC@Oncology@Preclinical@0@0@CureMeta
PF-06804103 PF 06804103 Anti-NG-HER2 ADC | Anti-NG-HER2 ADC | PF-06804103@Oncology@1@6@1@Pfizer
IPH43@Oncology / Hematology@@0@0@Innate | AstraZeneca
Anetumab corixetan@@@0@0@
ABBV-3373@Anti-TNF monoclonal antibodies / Antirheumatics@@0@0@AbbVie
BDC-1001@Oncology@3@72@22@Bolt
RN765C@Oncology@@0@0@Rinat | Pfizer
STI-6129 LNDS1001 | LNDS1001 | STI-6129 | CD38-077@@2@2@4@Sorrento Therapeutics
ZV05-mcMMAF | ZV05-ADC | ZV0501 | 5T4-MMAF ADC | 5T4-MMAF ADC ZV05-mcMMAF ZV0501@Oncology@@0@0@Zova Biotherapeutics | Concortis
AG02@Oncology@@0@0@A&G
Anti-RON-ADC | Zt/g4-DM1@@Preclinical@0@0@
SAR 566658 | SAR566658@Oncology@2@0@0@IMMUNOGEN | Sanofi
lintuzumab satetraxetan | 225Ac | Actinium@Oncology@2@2@2@AstraZeneca | Fusion Pharmaceuticals Inc
Mirzotamab Clezutoclax | ABBV-155@Oncology@2@0@0@AbbVie
ST8176AA1@Oncology@Preclinical@0@0@Alfasigma
SGN-CD228A  anti-CD228 -   Anti-CD228-MMAE | SGN-CD228A@Oncology@1@0@0@Seagen
PEN-221 | BTP-227 | PEN221@Oncology@2@0@0@Tarveda
PEN-866 | PEN 866 HDC SN-38 PEN866 PEN-866 STA-12-8666 STA-8666@Oncology@2@0@0@Tarveda
BT1718 | BT-1718 | BT 1718@Oncology@Preclinical@0@0@Bicycle Therapeutics
Satumomab Penditide | CYT-099 CYT-103 Indium In-111 satumomab pendetide Indium | OncoScint® CR/OV | 111In | satumomab pendetide Indium In 111 satumomab pendetide Indium-111 satumomab pendetide@Oncology@Approved@2@1@Knoll (Europe) | Lonza Biologics
DOTA-HUJ-591-GS DOTA-HUJ-591 HuJ591-DOTA | Rosopatamab Tetraxetan@Oncology@2@0@0@
OTSA-101-DTPA OTSA101-DTPA-90Y | OTSA-101-DTPA | Tabituximab Barzuxetan | OTSA101-SS01@Oncology@1@0@0@OncoTherapy Science (Japan)
ASP-1929  RM-1929 Cetuximab-irdye 700dx | RM-1929 | Cetuximab sarotalocan | ASP-1929@Oncology@3@0@0@Aspyrian | Rakuten Medical
Tamrintamab Pamozirine | SC-003 SC-003 ADC Anti-DPEP3 ADC hSC34.28-PBD1 DC-1728001 | Anti-DPEP3 ADC | SC-003@Oncology@1@0@0@Stemcentrx | AbbVie
ADCT-301 | ADCT-301 HuMax-TAC-ADC “Cami-T” | HuMax-TAC-ADC | Camidanlumab tesirine@Oncology/Hematology@2@0@0@Genmab | ADC Therapeutics
ABBV-647 | PF-06647020 | Cofetuzumab pelidotin | PF-06647020 PF06647020 ABBV-647 PTK7-ADC Anti-PTK7 ADC h6M24-vc0101 PF 7020@Oncology@2@6@3@AbbVie | Stemcentrx | Pfizer
RO7032005 | DCDS0780A | DCDS0780A DCDS 0780A RO7032005 | Iladatuzumab vedotin@Oncology Hematology@1@0@0@Genentech | Roche
Ladiratuzumab vedotin | SGN-LIV1A | Anti-LIV-1 ADC@Oncology@2@8@3@Seagen
ASG-15ME | AGS15C –SGD-1006 | Ha15-10ac12vcMMAE | AGS15E | AGS-15vcMMAE | Sirtratumab vedotin | AGS-15E | Ha15-10ac.1vcMMAE@Oncology / Hematology@1@0@0@Astellas | Ligand Pharmaceuticals | Seagen | Agensys
ABBV-321 | Serclutamab Talirine | ABBV-321 Anti-Egfr/pbd -  ABBV-321@Oncology@1@0@0@AbbVie
Losatuxizumab vedotin | ABBV-221 | ABBV-221 ABBV221@Oncology@2@0@0@AbbVie
CR011 CR011-vcMMAE | Glembatumumab vedotin | CDX-011@Oncology@3@9@4@Celldex
BMS-936561 | αCD70_MED-A | BMS936561 | MDX-1203@Oncology Hematology@1@1@1@Medarex
1-Oxopentyl]-Maytansine-Chimerized Anti-Cd138 Igg4 Monoclonal | BT-062 | Oxobuthyldithio | Indatuximab Ravtansine | BT-062 BT062 nBT062-DM4 also known as: N2'-Deacetyl-N2'-[4-Methyl-4@Oncology, Hematology@2@1@2@BioTest | IMMUNOGEN
Promiximab duocarmycin@Oncology@Preclinical@0@0@
MEDI3726 | ADCT-401 | Anti-PSMA/PBD ADC MEDI3726 ADCT-401@Oncology@1@3@1@AstraZeneca | MedImmune | ADC Therapeutics
MEDI 4276 | MEDI-4276 | MEDI4276@Oncology@1@1@1@AstraZeneca | MedImmune
BMS-986148 | BMS986148@Oncology@2@10@2@Bristol Myers Squibb
AXL-107-MMAE | HuMax-AXL-ADC AXL-107-MMAE Anti-AXL-ADC | Enapotamab vedotin | HuMax-AXL-ADC@Oncology@2@6@1@Genmab | Seagen
CX-2029@Oncology Hematology@2@4@1@AbbVie | CytomX
BMS986288 | BMS-986288 BMS986288 | BMS-986288@Oncology@2@0@0@Bristol Myers Squibb | CytomX
CD166 AADC | CX-2009 ADC CX-2009 | Praluzatamab Ravtansine | CX-2009 | CD166 PDC@Oncology@2@0@0@IMMUNOGEN | CytomX
hMN-14-SN38 hMN-14-SN-38 ADC hMN14-CL-SN-38 | hMN14-SN-38 | Labetuzumab govitecan | IMMU-130 | Labetuzumab-SN-38 IMMU-130@Oncology@2@1@1@Immunomedics
Epratuzumab Tesirine | ADC ADCT-602 -  ADCT-602 anti-CD22/PBD ADC ADCT-602 epratuzumab-cys-SG3249 epratuzumab-cys-tesirine hLL2-cys-PBD hLL2-cys-SG3249 | hLL2-cys-PBD | ADCT-602 | ADCT 602 ADCT602 ADCT-602@Oncology@2@1@1@ADC Therapeutics
OBI-999 Anti-Globo H ADC | Anti-Globo H ADC | OBI-999@Oncology@2@0@0@OBI Pharma
3A4-PL1601@Oncology@Preclinical@0@0@ADC Therapeutics
5F9vcMMAE | Indusatumab Vedotin | TAK-264 | TAK264 | MLN-0264 | MLN 0264 | MLN0264@Oncology@2@1@1@Takeda | Millennium
TAK-164 TAK164 Anti-GCC ADC Anti-GCC | TAK-164@Oncology@2@0@0@Takeda | Millennium
TR1801-ADC | TR1801-ADC MT-8633 | MT-8633@Oncology@1@1@1@Open Innovation Partners | AstraZeneca | MedImmune | Tanabe Research Laboratories USA
JBH492@Oncology Hematology@1@7@1@Novartis
NJH395 anti-HER2 ISAC NJH395 | NJH395@Oncology@1@4@1@Novartis
FS-1502 | FS-1502 Trastuzumab Monomethyl Auristatin F@Oncology@3@72@21@Shanghai Fosun
F0002-ADC | CD30-MCC-DM1 | F0002-ADC CD30-MCC-DM1@Hematology@1@1@1@Fudan-Zhangjiang
CC-99712 – Anti-BCMA ADC | CC-99712@Oncology@2@5@1@Sutro Biopharma | Celgene | Bristol Myers Squibb
Ab1-18Hr1 | AbGn-107@Oncology@1@0@0@AbGenomics BV
SHR-A1201@Oncology@@0@0@Jiangsu HengRui Medicine
SHR-A1403 | HTI-1066 | HTI-1066 SHR-A1403@Oncology@2@1@1@Jiangsu HengRui Medicine
AMG 224 | AMG 224 anti-BCMA–MCC–DM1@Oncology Hematology@1@0@0@Amgen
GQ1001 | GQ1001 – HER2@Oncology@2@3@3@GeneQuantum (Suzhou, China)
GQ1003 – TROP2@Oncology@@0@0@GeneQuantum (Suzhou, China)
GQ1005 – HER2@Oncology@1@1@1@GeneQuantum (Suzhou, China)
GC1007@Oncology@Preclinical@0@0@GeneQuantum (Suzhou, China)
GC1009@Oncology@Preclinical@0@0@GeneQuantum (Suzhou, China)
GQ1014@Oncology@@0@0@GeneQuantum (Suzhou, China)
GQ1015@Oncology@@0@0@GeneQuantum (Suzhou, China)
GQ1017@Oncology@Preclinical@0@0@GeneQuantum (Suzhou, China)
GQ1018@Oncology@Preclinical@0@0@GeneQuantum (Suzhou, China)
RC-48 RC 480-ADC RC48 | RC-48 | Aidixi® | Disitamab Vedotin | RC48 | 爱地希® | RC 480-ADC@Oncology@Approved@13@50@RemeGen | MabPlex
RC108@Oncology@2@1@2@RemeGen | MabPlex
ADCT-901@Oncology@Preclinical@0@0@ADC Therapeutics
XB002 ICON-2 Tissue Factor ADC | ICON-2 Tissue Factor ADC  XB002@Oncology@1@9@1@Exelixis | Iconic | Zymeworks
MRG004A@Oncology@2@2@1@Lepu Biopharma | Shanghai Miracogen
REGN3124-PBD@Oncology@Preclinical@0@0@Regeneron
CLDN18.2 ADC | SOT102 | SO-N102@Oncology@3@5@2@SOTIO Bio
DHES0815A | anti-HER2/PBD-monoamide anti-HER2/PBD-MA | DHES0815A RG6148 ADC DHES0815A anti-HER2/PBD-MA ADC  hu7C2- disulfide-PBD-MA | RG6148@Oncology@1@0@0@Genentech | Roche
Loncastuximab tesirine | ADCT-402 | ADCT-402 RB4v1.2-SG-3249 | Zynlonta@Oncology/Hematology@Approved@6@3@ADC Therapeutics
Tivdak | HuMax®-TF-ADC | TF-011-MMAE  HuMax-TF-ADC | Tisotumab Vedotin@Oncology@Approved@36@21@Genmab | Seagen
SGN-PDL1V@Oncology@Preclinical@0@0@Seagen
Ifinatamab Deruxtecan – DS-7300a | DS-7300a | MABX-9001a@Oncology@3@24@3@DAIICHI SANKYO
Anti-ROR2 ADC | BA3021 Anti-ROR2 ADC  CAB-ROR2-ADC | BA3021 | Ozuriftamab Vedotin | CAB-ROR2-ADC@Oncology@2@8@2@BioAtla
CAB-Axl-ADC | CAB-anti-Axl-ADC | Mecbotamab Vedotin | CAB-anti-Axl-ADC BA3011 | BA3011@Oncology; Hematology@2@8@2@Sinobioway Biomedicine | BioAtla
SBT6050 | Pertuzumab Zuvotolimod@Oncology@3@53@16@Silverback
OG1953 | KSI 301 | Tarcocimab Tedromer | KSI301 | KSI-301@Ophthalmology Immunology;@3@12@2@Kodiak Sciences
BAY 2635190 | Trastuzumab Corixetan | BAY-2635190 | BAY2635190@Oncology@3@72@20@Bayer
AEX4089DC1 | AEX4089DC1 Anti-B7-H3 ADC | Anti-B7-H3 ADC | MGC018 | Vobramitamab Duocarmazine@Oncology@2@1@1@MacroGenics
PSMA-TTC PSMA targeted thorium-227 | PSMA-TTC | BAY-2315497 | Pelgifatamab Corixetan@Oncology@1@3@1@Bayer
WT1-RTA | Grisnilimab setaritox@Immunology@3@0@0@Xenikos
SPV-T3a-RTA | Dafsolimab Setaritox@Immunology@3@0@0@Xenikos
Mipasetamab Uzoptirine | ADCT-601@Oncology@1@0@0@ADC Therapeutics
Zalsenertant Tetraxetan | Lutetium Lu 177 Zalsenertant Tetraxetan@Oncology@@0@0@
Pivekimab Sunirine | IMGN-632 | MGN 632 | IMGN 632 | IMGN632@Oncology@2@6@4@IMMUNOGEN
IMGC936@Oncology@2@3@1@IMMUNOGEN | MacroGenics
IMGN151@Oncology@1@1@1@IMMUNOGEN
PRO1184@Oncology@2@2@1@ProfoundBio
PRO1160@Oncology@@0@0@ProfoundBio
ETx-22@Oncology@Preclinical@0@0@Emergence
HS-20089@Oncology@2@1@3@Shanghai Hansoh Biomedical
AZD8205@Oncology@2@15@1@AstraZeneca
SGN-B7H4V@Oncology@1@0@0@Seagen
TORL-2-307-ADC@Oncology@1@2@1@Translational Research in Oncology | TORL Biotherapeutics
Anti-CD269-ADC | Anti-CD269-amanitin-ADC | Anti-BCMA | HDP-101 | Anti-BCMA-ATAC | anti-BCMA-ADC@Oncology; Hematology@2@0@1@Heidelberg Pharma
MGTA-117 – Amanitin ADC@Oncology / Hematology@2@0@0@Heidelberg Pharma | Magenta
A166 ADC | A166 ADC A166 anti-HER2 ADC A166@Oncology@2@1@1@KLUS
SKB315@Oncology@1@1@1@KLUS
SKB264 ADC@Oncology@3@33@3@KLUS
AMG-595 | AMG595@Oncology@1@0@0@Amgen
DS-9606a | DS-9606-a@Oncology@1@0@0@DAIICHI SANKYO
YL201@Oncology@2@2@2@MediLink
BB-1705@Oncology@2@1@1@Bliss (Hangzhou)
J6M0-mcMMAF | Blenrep® | Belantamab mafodotin | GSK2857916  2857916 GSK '916 J6M0-mcMMAF | GSK2857916@Oncology@Approved@30@15@GlaxoSmithKline | Seagen
RC118@Oncology@2@1@2@Biocytogen | MabPlex | RemeGen
SYS6002 | CRB-701@Oncology@2@4@1@Corbus
PYX-201@Oncology@1@0@0@Pyxis Oncology
Anti 5T4 ADC SYD1875 | SYD1875@Oncology@1@2@1@Byondis
BYON3521 | BYON3521 ADC@Oncology@1@4@1@Byondis
BYON4413 ADC | BYON4413 BYON4413 ADC@Oncology@1@3@1@Byondis
PSMA-ADC@Oncology@2@0@0@Progenics Pharmaceuticals
Anti-CD74-ADC | STRO-001@Oncology@1@1@1@Sutro Biopharma
SYD985 | Trastuzumab vc-seco-DUBA | Trastuzumab valine-citrulline-seco-duocarmycinhydroxybenzamide-azaindole | Trastuzumab duocarmazine | SYD 985@Oncology@3@58@24@Byondis | Synthon Pharmaceuticals Durham, NC
BAT8007@Oncology@1@0@0@Bio thera Solutions
ABBV-319@Oncology@1@0@0@AbbVie
ABBV-400@Oncology@1@0@0@AbbVie
ABBV-706@Oncology@1@0@0@AbbVie
GMF-1A3 | GMF-1A3-MMAE@Oncology@Preclinical@0@0@
TH1902 | Sudocetaxel Zendusortide@@3@53@19@Theratechnologies
XMT-1536 | Upifitamab Rilsodotin | UpRi | XMT-1536 XMT 1536 UpRi Upifitamab Rilsodotin | XMT1536@Oncology@3@0@0@Mersana
M9346A-sulfo-SPDB-DM4 | Mirvetuximab Soravtansine | IMGN853 | IMGN-853 | Elahere | Anti-FOLR1 monoclonal -maytansinoid@Oncology@Approved@27@16@IMMUNOGEN
Basiliximab Sarotalocan@Oncology@2@0@0@
Maridebart cafraglutide@@2@0@0@
Oberotatug Ravtansine@Oncology@2@0@0@
Puxitatug samrotecan@@2@0@0@
Trastuzumab Botidotin@Oncology@3@72@20@RemeGen
REGN5093 – M114@Oncology@2@1@1@Regeneron
M1231@Oncology@1@2@1@Sutro Biopharma
DS-8201 | DS-8201a | Trastuzumab deruxtecan | ENHERTU®@Oncology@Approved@64@90@AstraZeneca | DAIICHI SANKYO
BL-B01D1@Oncology@1@0@0@Systimmune | Sichuan Baili
BAT8001@Oncology@3@0@0@Bio thera Solutions
BAT8003@Oncology@1@0@0@Bio thera Solutions
IMMU-132 | hRS7-[CL-SN-38] hrS7-SN-38 | Sacituzumab govitecan | hRS7-SN-38 | hRS7-SN38 | Trodelvy | hRS7-SN-38-ADC@Oncology@Approved@46@67@GILEAD | Immunomedics
GQ1010@Oncology@2@1@1@GeneQuantum (Suzhou, China) | Pyramid Biosciences
ZB131-MMAE | ZB131-DXd | ZB131 | ZB131  ZB131-MMAE  ZB131-DXd@Oncology@2@0@0@ZielBio
BB-1701 | HER2-Targeting ADC@Oncology@2@2@1@Bliss (Hangzhou) | Eisai
TQB2103@Oncology@1@1@1@Sino Biopharmaceutical
LM-302 BMS-986476 TPX-4589 | TPX-4589 | BMS-986476 | LM-302@Oncology@2@0@0@LaNova | Turning Point therapeutics
CMG901@Oncology@2@16@2@Lepu Biopharma | AstraZeneca | KYM Biosciences | Keymed Biosciences
ABBV-011@Oncology@1@0@0@AbbVie
DB-1303 | DB-1303 BNT323 | BNT323@Oncology@3@0@1@Duality Biologics
DB-1311@@@0@0@Duality Biologics
XMT-2056 anti-HER2-STING agonist -  XMT-2056 HER2-targeted STING agonist ADC XMT-2056 STING agonist ADC XMT-2056 | XMT-2056@Oncology@1@0@0@GlaxoSmithKline | Mersana
ABBV-399 ABBV399 ABBV 399 ABT-700-vcMMAE Teliso-V cMet-Targeted ADC | ABT-700-vcMMAE | Telisotuzumab Vedotin | ABBV 399 | ABBV-399 | Teliso-V@Oncology@3@40@5@AbbVie
Lorvotuzumab mertansine | IMGN-901 | BB-10901 IMGN901 huN901-DM1 IMGN-901 | huN901-DM1@Oncology | Hematology@2@3@5@IMMUNOGEN
U3-1402 U3-1402A Anti-HER3 | HER3 ADC | Patritumab Deruxtecan | U3-1402@Oncology@3@8@5@Amgen | DAIICHI SANKYO
TROP2 ADC | Datopotamab deruxtecan | DS-1062 DS1062 DS-1062A Anti-TRP2/dxd | DS-1062@Oncology@3@42@24@AstraZeneca | DAIICHI SANKYO
SAR408701 SAR 408701 SAR-408701 | Tusamitamab Ravtansine | SAR408701 | SAR-408701 | SAR 408701@Oncology@3@0@0@IMMUNOGEN | Sanofi
MORAb-202 MORAb-003-VCP-eribulin | Farletuzumab Ecteribulin | MORAb-202@Oncology@3@28@8@Morphotek | Eisai
LM-305@Oncology/Hematology@1@0@0@AstraZeneca
ATG-022@Oncology@1@0@0@Antengene
CPO301@Oncology@1@2@1@CSPC Pharmaceutical Group
W0101 | W0101 W-0101 | Lonigutamab Ugodotin | W-0101@Oncology@2@2@1@Pierre Fabre | Roche
Trastuzumab rezetecan SHR-A1811 | Trastuzumab rezetecan | SHR-A1811@Oncology@3@72@26@Luzsana Biotechnology
cMET-ADC MYTX-011 | MYTX-011@Oncology@1@6@1@Mythic Therapeutics
DP303c@Oncology@3@1@1@CSPC Pharmaceutical Group
PR-1498487-MMAE PR-1498487 PAB-MMAE | ABBV-085 | Anti-huLRRC15 -  anti-huLR C15 ADC ABBV-085 | PR-1498487-MMAE | Samrotamab vedotin@Oncology@2@3@1@AbbVie
JS108@Oncology@1@0@0@Shanghai Junshi
anti-PSMA ADC | ARX517 | ARX517-PSMA-ADC@Oncology@2@1@6@Progenics Pharmaceuticals | Ambrx
EO-3021 also known as SYSA1801@@1@2@1@Elevation Oncology | CSPC Pharmaceutical Group
CUSP06@Oncology@1@1@1@OnCusp Therapeutics
BAT8006@Oncology@@0@0@Bio thera Solutions
ADRX-0706@Oncology@1@1@1@Adcentrx
BRY812@Oncology@1@0@0@BioRay
Raludotatug Deruxtecan  DS-6000a R-DXd | DS-6000a R-DXd | Raludotatug Deruxtecan@Onclology@3@4@1@DAIICHI SANKYO
SGN-CEACAM5C@Oncology@1@0@0@Seagen
HLX43@Oncology@1@1@1@Shanghai Henlius
HBM9033@Oncology@@0@0@Pfizer | Nona Bioscience
SGN-B6A@Oncology@3@0@0@Pfizer | Seagen
STRO-002 STRO 002 SP8193 | Luveltamab Tazevibulin – SΤRO-002 – Luvelta@Oncology@3@8@4@Sutro Biopharma
OBI-992 | BSI-992@Oncology@2@1@1@OBI Pharma | Biosion (China)
STRO-003@Oncology@@0@0@Sutro Biopharma
STRO-004@Oncology / Hematology@@0@0@Sutro Biopharma
VLS-101 MK-2140 | VLS-101 | Zilovertamab vedotin | MK-2140@Hematology Oncology@3@0@0@VelosBio | Merck KGaA, Darmstadt, Germany | Merck Sharp & Dohme
BHV-1500@Oncology/Hematology@Preclinical@0@0@Biohaven
BHV-1510@Oncology@Preclinical@0@0@Biohaven
AMT-562@Oncology@1@0@0@Multitude
RC88@Oncology@2@1@1@RemeGen | MabPlex
9MW2821@Oncology@2@0@0@Mabwell (Shanghai)
HER3-ADC | Elevation Oncology – Proof of Concept ADC@Oncology@1@0@1@Elevation Oncology
WAY-CMA-676 | Gemtuzumab ozogamicin | CMA-676 | CDP-771 | hP67.6-calicheamicin | Mylotarg®@Oncology@Approved@24@28@Pfizer | WYETH
SGN35 | Brentuximab vedotin | Adcetris® | SGN-35 cAC10-Val-Cit-MMAE@Oncology@Approved@38@78@Takeda | Seagen
MRG003@Oncology@3@1@5@Lepu Biopharma | Shanghai Miracogen
TAA013@Oncology@3@0@0@TOT Biopharm
ZW49 HER2 x HER2 Bispecific | ZW49 | Zanidatamab Zovodotin@Oncology@2@2@1@BeiGene | Zymeworks
ABBV-154@@2@0@0@AbbVie
MRG002@@3@72@24@Shanghai Miracogen
PSMA ADC therapeutic@@2@1@5@Progenics Pharmaceuticals
Milatuzumab-doxorubicin@@3@54@37@Immunomedics
XMT-1592@@2@0@0@Mersana
CX2029@@2@0@0@CytomX
FOR46@@2@1@3@Fortis Therapeutics
INBRX-109@@1@0@0@Inhibrx
ABBV-CX-2029@@2@4@1@AbbVie | CytomX
TAK-500@@1@0@0@Takeda
SGN-CD30C@@1@0@0@Seagen
MEDI2228@@1@5@1@AstraZeneca
DS-6157@@1@0@0@DAIICHI SANKYO
CLT030@@1@0@0@Cellerant Therapeutics
ADC-1013@@3@4@2@Alligator Bioscience AB
Glypican3-ADC@@1@0@0@Bristol Myers Squibb
CA9-ADC@@1@0@0@MorphoSys AG
ADC-1001@@Preclinical@0@0@Alligator Bioscience AB
ADC-3680@@2@0@0@Argenta Discovery Ltd
d-trastuzumab@@3@72@20@IATRICa Inc
ADC-1012@@Preclinical@0@0@Alligator Bioscience AB
Maclizumab@@Preclinical@0@0@Cytoguide ApS
ADC-7828@@Preclinical@0@0@Argenta Discovery Ltd
CD79-targeted immunotoxins@@2@0@1@Genentech
ADC-5510@@Preclinical@0@0@Adolor Corp
ADC-9971@@Preclinical@0@0@Argenta Discovery Ltd
OP-06@@Preclinical@0@0@Onco-Pharmakon Inc
DSTA-4637S@@1@0@0@Genentech
BAY 2315497@@3@0@0@Progenics Pharmaceuticals
ADC-03@@Preclinical@0@0@Almac Discovery
ADC-01@@Preclinical@0@0@Almac Discovery
YH012@@Preclinical@0@0@Biocytogen
YH013@@Preclinical@0@0@Biocytogen
90Y-CYT-356 | CYT-356-90Y | YTTRIUM Y 90 CAPROMAB PENDETIDE | CYT-356 90Y | ONCOLTAD | CYT-356-Y-90@@4@0@0@
Altumomab pentetate | HYBRI-CEAKER | INDIUM IN 111 ALTUMOMAB PENTETATE | ZCE025 | ZCE-025 | ALTUMOMAB | MAB-35 | ALTUMOMAB PENTETATE@@1@0@0@
BEVACIZUMAB GAMMA@@3@24@13@Merck KGaA, Darmstadt, Germany | EMD Serono
IODINE I 131 DERLOTUXIMAB BIOTIN | IODINE (131I) DERLOTUXIMAB BIOTIN | Cotara | IODINE I-131 DERLOTUXIMAB BIOTIN@@2@0@0@
OPELKIBART ELMANITIN@@2@0@0@
SP-8166 | SP8166 | LUVELTAMAB TAZIDE@@3@6@1@Sutro Biopharma | GOG Foundation
DELPACIBART ETEDESIRAN@@2@0@0@
111INDIUM-ZEVALIN | INDIUM IN 111 IBRITUMOMAB TIUXETAN | IBRITUMOMAB TIUXETAN IN-111 | ZEVALIN INDIUM IN-111 | ZEVALIN IN-111@@1@0@0@
90Y-DOTA-HMN14 | YTTRIUM Y 90 LABETUZUMAB TETRAXETAN@@1@0@0@
ZIRCONIUM Zr 89 CREFMIRLIMAB BERDOXAM | ZIRCONIUM ZR 89 CREFMIRLIMAB BERDOXAM@@2@0@0@
Taplitumomab paptox | TAPLITUMOMAB PAPTOX@@2@0@0@
ANTI-MELANOMA MAB FRAGMENTS | Tecnemab K1@@4@0@0@
Nacolomab tafenatox | NACOLOMAB TAFENATOX@@2@0@0@
TELIMOMAB ARITOX | Telimomab aritox | T101 | T-101@@2@1@1@ADC Therapeutics
KSA-INTERLEUKIN-2 | HUKS-IL2 | EMD-273066 | TUCOTUZUMAB CELMOLEUKIN | EMD 273066@@2@0@0@
ADALIMUMAB FOSIMDESONIDE@@2@0@0@
BICIROMAB BRALLOBARBITAL | T2G1S | FIBRISCINT | Biciromab brallobarbital@@1@0@0@
IZALONTAMAB BRENGITECAN@@2@0@0@
90Y IBRITUMOMAB TIUXETAN | YTTRIUM Y 90 IBRITUMOMAB TIUXETAN | IBRITUMOMAB TIUXETAN YTTRIUM Y-90 | (90)Y-IBRITUMOMAB TIUXETAN | 90Y-IBRITUMOMAB | IBRITUMOMAB TIUXETAN Y-90 | YTTRIUM Y-90 IBRITUMOMAB TIUXETAN@@4@0@0@
DORLIMOMAB ARITOX | Dorlimomab aritox | ST-1 4197X-RA | MDX-RA@@2@0@0@
PNU-214936 | ABR-214936 | ANATUMOMAB MAFENATOX | Anatumomab mafenatox | ANYARA@@3@9@5@Active Biotech AB
IMCIROMAB PENTETATE | MYOSCINT INDIUM IN-111 | IMCIROMAB | INDIUM IN 111 IMCIROMAB PENTETATE | INDIUM IN-111 IMCIROMAB PENTETATE | INDIUM IN-111 MYOSCINT | INDIUM (111IN) IMCIROMAB@@4@0@0@
Enfortumab | ASG-22ME | AGS-22ME | AGS-22CE | ASG-22CE | AGS-22M | ASG-22MSE | Enfortumab Vedotin | Padcev | AGS-22M6E | Enfortumab vedotin@Oncology@Approved@22@10@Astellas | Seagen
LMB-1@@2@0@0@
Citatuzumab bogatox | CITATUZUMAB BOGATOX | VB6-845@@2@0@0@
Moxetumomab pasudotox | Lumoxiti | HA-22 | HA22 | MOXETUMOMAB PASUDOTOX | CAT-8015 | MOXETUMOMAB PASUDOTOX TDFK@@4@14@4@MedImmune
LMB-7@@1@0@0@
Proxinium, Vicinium | Vicineum | VB4-845 | XD60E5X7FI | PROXINIUM | OPORTUZUMAB MONATOX | VICINIUM | 4D5MOCB-ETA@@3@0@0@
ALEMTUZUMAB BETA@@2@0@0@
DINUTUXIMAB BETA | Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron)@@4@0@0@
BETALUTIN | TETULOMAB TETRAXETAN LU-177 | (SUP 177)LU-TETULOMAB | 177LU-TETULOMAB | 177LU-TETRAXETAN-TETULOMAB@@2@24@1@Nordic Nanovector
SIGVOTATUG VEDOTIN@@2@0@0@
2F35K89X9W | 90Y-EPRATUZUMAB | S9S0Y-DOTA-HLL2 | 90Y-DOTA-HLL2 | YTTRIUM Y 90 EPRATUZUMAB TETRAXETAN | Y-90-DOTA-HLL2 | (SUP 90)Y-DOTA-HLL2@@2@0@0@
ORTHOZYME CD 5 PLUS | ZOLIMOMAB ARITOX | XOMA ZYME H 65 | H-65RTA | ZX-CD5 | H-65-RTA | H65-RTA@@2@0@0@
CERGUTUZUMAB AMUNALEUKIN | RG-7813 | RO-6895882 | RO6895882 | RG7813@@2@0@0@
VERLUMA | Nofetumomab merpentan 99Tc | TECHNETIUM (99MTC) NOFETUMOMAB MERPENTAN | NOFETUMOMAB MERPENTAN 99TC | TECHNETIUM TC 99M NOFETUMOMAB MERPENTAN@@4@0@0@
HAFP-31 | YTTRIUM Y 90 TACATUZUMAB TETRAXETAN | YTTRIUM (90Y) TACATUZUMAB TETRAXETAN | AFP-CIDE@@2@0@0@
CMD-193@@1@0@0@
SP-8893 | ISPECTAMAB TAZIDE@@2@0@0@
LMB-2@@2@0@0@
TRASTUZUMAB BRENGITECAN@@3@72@20@RemeGen
LMB-9 | B3 (DSFV) -PE (PSEUDOMONAS AERUGINOSA EXOTOXIN A)38@@1@0@0@
ASG-5ME@@1@1@1@Seagen | Agensys
SACITUZUMAB TIRUMOTECAN@@3@54@2@GOG Foundation | Merck Sharp & Dohme
BEZETABART DEBOTANSINE@@2@0@0@
ARX-788 MAB | ANVATABART PACTIL | ARX788 mAb@@2@5@3@Ambrx
HUMY9-6 | AVE-9633@@1@0@0@
DP-303c@@@0@0@
DCLL-9718S@@@0@0@
BVX-001@@@0@0@
IMMU-114@@@0@0@
Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197  vaccine@@@0@0@
AOC-1020@@@0@0@
AOC 1001@@@0@0@
Tositumomab I-131@@@0@0@
LMB-100@@@0@0@
Zenocutuzumab@@@0@0@
Mitazalimab@@3@1@1@Alligator Bioscience AB
Nendratareotide uzatansine@@@0@0@
AGS67E@@1@2@1@Astellas
AGX101@@1@1@1@Angiex
AMT-151@@1@2@1@Multitude
AZD9592@@1@11@1@AstraZeneca
BAT8009 for Injection | BAT8009@@1@1@1@Bio thera Solutions
BB-1709@@1@1@1@Bliss (Hangzhou)
BG-C9074@@1@1@1@BeiGene
BGB-C354@@1@0@1@BeiGene
BIO-106@@2@1@1@BiOneCure Therapeutics Inc
B003@@1@1@1@Shanghai Pharmaceuticals Holding
CA102N@@2@0@1@Holy Stone Healthcare Co., Ltd
CS5001@@1@3@1@CStone Pharmaceuticals
FDA018-ADC@@1@1@1@Fudan-Zhangjiang
FDA022 Monoclonal -  for injection Phase Ib | FDA022 | FDA022 Monoclonal -  for injection Phase Ia@@2@1@2@Fudan-Zhangjiang
DXC006@@1@0@1@Hangzhou DAC Biotechnology Co., Ltd
EBC-129@@1@2@1@EDDC (Experimental Drug Development Centre), A*STAR Research Entities
FZ-AD004@@1@1@1@Fudan-Zhangjiang
HLX42@@1@1@1@Shanghai Henlius
HS-20093 (Phase Ib: Dose expansion) | HS-20093 | HS-20093 (Phase Ia: Dose escalation)@@2@1@3@Shanghai Hansoh Biomedical
HS-20105@@2@0@1@Shanghai Hansoh Biomedical
JSKN003@@1@1@1@Alphamab Oncology
KM501@@1@1@1@Xuanzhu Biopharm
L-DOS47@@3@2@3@Pharm-Olam International | Helix BioPharma
LCB84@@2@2@1@AntibodyChem Biosciences | Legochem
LY4052031@@1@1@1@Eli Lilly | Loxo Oncology
LY4101174@@1@3@1@Eli Lilly | Loxo Oncology
LY4170156@@1@1@1@Eli Lilly | Loxo Oncology
M9140@@1@24@1@Merck KGaA, Darmstadt, Germany | EMD Serono
ORM-5029@@1@1@1@Orum Therapeutics USA, Inc
PBI-410@@2@1@1@Biohaven
SIBP-A13 | SIBP-A13 formulation for injection@@1@0@1@Shanghai Institute Of Biological Products
TAC-001@@2@2@1@Tallac Therapeutics
TAK-853@@2@1@1@Takeda
TORL-1-23@@1@1@1@Translational Research in Oncology | TORL Biotherapeutics
TORL-3-600@@1@2@1@Translational Research in Oncology | TORL Biotherapeutics
TORL-4-500@@1@1@1@Translational Research in Oncology | TORL Biotherapeutics
TQB2102 | TQB2102 for injection | TQB2102 injection@@2@1@5@Chiatai Tianqing
TUB-040@@2@1@1@Tubulis
VIP943@@1@1@1@Vincerx Pharma, Inc
WTX212A | WTX212A injection@@1@1@1@Westlake Therapeutics
YL202 should be intravenously infused | YL202@@2@1@2@MediLink
AMG 595@@1@2@1@Amgen
